Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Invasive Bladder Cancer × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Head and Neck Neoplasms 112 Lung Neoplasms 110 Glioblastoma 109 Carcinoma, Non-Small-Cell Lung 102 Lymphoma 96 Breast Neoplasms 96 Squamous Cell Carcinoma of Head and Neck 82 Central Nervous System Neoplasms 76 Prostatic Neoplasms 74 Leukemia 67 Gliosarcoma 63 Pancreatic Neoplasms 62 Esophageal Neoplasms 59 Rectal Neoplasms 58 Precursor Cell Lymphoblastic Leukemia-Lymphoma 57 Brain Neoplasms 54 Lymphoma, Large B-Cell, Diffuse 51 Lymphoma, Follicular 48 Hodgkin Disease 46 Lymphoma, Non-Hodgkin 45 Burkitt Lymphoma 43 Sarcoma 38 Lymphoma, Large-Cell, Immunoblastic 38 Leukemia, Lymphocytic, Chronic, B-Cell 38 Lymphoma, Mantle-Cell 33 Myelodysplastic Syndromes 32 Astrocytoma 32 Adenocarcinoma Of Esophagus 32 Lymphoma, B-Cell, Marginal Zone 31 Glioma 30

Interventions

tremelimumab 1 durvalumab 1 Sodium Chloride 1 Radiotherapy 1 Lidocaine 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡